BerGenBio to Present Clinical Data From Phase II Trial With Selective AXL Inhibitor at 34th Annual SITC Meeting

Corporate Breaking News

Home : BerGenBio to Present Clinical Data From Phase II Trial With Selective AXL Inhibitor at 34th Annual SITC Meeting

Oct 02 2019	BerGenBio to Present Clinical Data From Phase II Trial With Selective AXL Inhibitor at 34th Annual SITC Meeting
BERGEN, Norway, Oct. 2, 2019 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, is pleased to announce it has been accepted for an oral presentation at the Society for...


Source:https://www.prnewswire.com:443/news-releases/bergenbio-to-present-clinical-data-from-phase-ii-trial-with-selective-axl-inhibitor-at-34th-annual-sitc-meeting-300929422.html

Related News
» Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum » Tissue World São Paulo abordará Fabricação Inteligente e o Comprador em painéis de discussão